- Home
- BRKR vs TLX Comparison
BRKR vs TLX Comparison
Compare BRKR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- TLX
- Stock Information
- Founded
- BRKR 1960
- TLX 2015
- Country
- BRKR United States
- TLX Australia
- Employees
- BRKR N/A
- TLX N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- BRKR Industrials
- TLX Health Care
- Exchange
- BRKR Nasdaq
- TLX Nasdaq
- Market Cap
- BRKR 5.7B
- TLX 5.7B
- IPO Year
- BRKR 2000
- TLX N/A
- Fundamental
- Price
- BRKR $36.73
- TLX $16.81
- Analyst Decision
- BRKR Buy
- TLX Strong Buy
- Analyst Count
- BRKR 12
- TLX 1
- Target Price
- BRKR $57.50
- TLX $22.00
- AVG Volume (30 Days)
- BRKR 2.5M
- TLX 18.3K
- Earning Date
- BRKR 05-07-2025
- TLX 01-01-0001
- Dividend Yield
- BRKR 0.55%
- TLX N/A
- EPS Growth
- BRKR N/A
- TLX 798.14
- EPS
- BRKR 0.52
- TLX 0.09
- Revenue
- BRKR $3,446,100,000.00
- TLX $484,687,790.00
- Revenue This Year
- BRKR $6.37
- TLX N/A
- Revenue Next Year
- BRKR $4.64
- TLX N/A
- P/E Ratio
- BRKR $69.90
- TLX $185.18
- Revenue Growth
- BRKR 14.84
- TLX 55.85
- 52 Week Low
- BRKR $34.10
- TLX $13.61
- 52 Week High
- BRKR $72.94
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- BRKR 44.01
- TLX N/A
- Support Level
- BRKR $34.98
- TLX N/A
- Resistance Level
- BRKR $37.97
- TLX N/A
- Average True Range (ATR)
- BRKR 1.25
- TLX 0.00
- MACD
- BRKR 0.03
- TLX 0.00
- Stochastic Oscillator
- BRKR 32.35
- TLX 0.00
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.